Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRT-201 in AVF Creation for CKD
NCT01305824Phase 2Completed
- Sponsor
- Proteon Therapeutics
- Start
- Mar 2011
- Primary completion
- Nov 2012
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vonapanitase in arteriovenous fistula stenosis (3 arms), sponsored by Proteon Therapeutics. Primary endpoints: Primary Arteriovenous Fistula Patency at 12 months and Number of participants with adverse events at 12 months. Started Mar 2011; status: completed.
02
Drugs
vonapanitase
03
Conditions
arteriovenous fistula stenosis
Beyond the preview
Go deeper on NCT01305824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01305824.